Click on headlines below to download research

Continuing to gain clinical data in eye disease
ReNeuron Group | 15/01/2021

After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues…

Funding to complete Phase IIa and other projects
ReNeuron Group | 08/12/2020

ReNeuron is focused on human retinal progenitor cell therapy (hRPC) for retinitis pigmentosa (RP). Ongoing Phase IIa data show a stable average gain in…

Exploiting the potential of cell therapy
ReNeuron Group | 26/08/2020

ReNeuron has refocussed onto its human retinal progenitor cell (hRPC) as shown in the last business update and in the FY20 results. hRPC, now the lead…